Institution
Liaoning University of Traditional Chinese Medicine
Education•Shenyang, China•
About: Liaoning University of Traditional Chinese Medicine is a education organization based out in Shenyang, China. It is known for research contribution in the topics: Randomized controlled trial & Acupuncture. The organization has 2040 authors who have published 1326 publications receiving 14664 citations.
Topics: Randomized controlled trial, Acupuncture, Apoptosis, Cancer, Portulaca
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The results suggest TNA could activate KLF4 and enhance autophagy as well as M2 polarization of macrophages by inhibiting miR‐375 to Attenuate Atherosclerosis.
57 citations
••
TL;DR: BOL is a novel therapeutic STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models and can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.
Abstract: STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in ~70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure–activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was observed in a STAT3−/− tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.
56 citations
••
TL;DR: The results suggest that cotreatment with BZYQD and cisplatin may represent a novel approach in treatment for NSCLC and thus offer a new target for chemotherapy.
Abstract: Cisplatin is one of the most active cytotoxic agents for non-small cell lung cancer (NSCLC) treatment. However, the development of cisplatin resistance is common. Bu-Zhong-Yi-Qi decoction (BZYQD), a Chinese traditional herbal medicine, is widely used for the enhancement of antitumor effect in other medications. In this study, we evaluated the effect and drug-resistance reversal mechanism of BZYQD combined with cisplatin on cisplatin-resistant A549/DDP cells. Our results showed that BZYQD exhibited direct cytotoxic and chemosensitizing effects. Cotreatment with BZYQD and cisplatin induced intrinsic apoptotic pathways which were measured by condensed nuclear chromatin, Annexin V/PI apoptosis assay, and apoptosis related proteins expression. In addition, cotreatment with BZYQD and cisplatin also activated autophagy, as indicated by an increase in LC3 puncta, classical autophagosomes and/or autolysosomes, and an accumulation of LC3-II and ATG7 protein. Finally, cotreatment with BZYQD and cisplatin resulted in the generation of ROS and scavenging ROS by NAC almost completely suppressing cell death. These results suggest that cotreatment with BZYQD and cisplatin might reverse cisplatin resistance by inducing ROS accumulation, which activates apoptosis and autophagy by oxidative stress. The combination of BZYQD and cisplatin may represent a novel approach in treatment for NSCLC and thus offer a new target for chemotherapy.
55 citations
••
TL;DR: This study finds that bone marrow-derived NSCs transduced with NT-3 reduced central nervous system inflammation and neurological deficits in ongoing EAE significantly more than conventional NSC therapy, and could pave the way to an easily accessible and highly effective therapy for CNS inflammatory demyelination.
55 citations
••
TL;DR: The results suggest that abnormal expression/regulation of microRNAs may contribute to or be indicative of the initiation and progression of MG.
54 citations
Authors
Showing all 2045 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hang Xiao | 64 | 618 | 16026 |
Muhammad Riaz | 58 | 934 | 15927 |
Jianping Liu | 45 | 333 | 7977 |
Guoan Luo | 45 | 221 | 6358 |
Xingshun Qi | 40 | 308 | 5409 |
Mei Wang | 29 | 201 | 6007 |
Xiaozhong Guo | 28 | 142 | 2269 |
Zhiwei Cao | 27 | 110 | 2879 |
Xinggang Yang | 26 | 113 | 2292 |
Ruixin Zhu | 25 | 110 | 2119 |
Ran Wang | 23 | 157 | 1942 |
Li-Ping Bai | 22 | 95 | 1824 |
Ke Liu | 19 | 31 | 1183 |
Ahmed M. Metwaly | 17 | 51 | 682 |
Kailin Tang | 17 | 40 | 919 |